{"success":true,"data":{"pressRelease":{"id":"115107","rtpr_id":"nGNX7pPZxD","ticker":"CVRX","exchange":"NASDAQ","all_tickers":["CVRX"],"title":"CVRx Announces Sales Leadership Transition","author":"Globe Newswire","published_at":"2026-08-11T11:00:00.458Z","article_body":"MINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)\n(\"CVRx\"), a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases, today announced that Robert John, Chief\nRevenue Officer, will depart the company, and that Paul Verrastro will assume\nthe role of Interim Head of Sales, effective immediately.  In his new role,\nMr. Verrastro will lead CVRx's sales organization while the company conducts a\nsearch for a permanent successor.\n\nMr. Verrastro brings more than 30 years of medical device sales and marketing\nexperience to the role. He has been with CVRx for over five years and recently\nmoved into a new senior advisor role focused on commercial execution\nsupport.  Prior to assuming this role, he was most recently Chief Marketing\nand Strategy Officer. Prior to joining CVRx, he held sales and marketing\nleadership positions at Guidant, Boston Scientific and Medtronic, much of that\nwork focused on bringing novel therapies and technologies to market, including\nimplantable cardioverter defibrillators (ICDs) and cardiac resynchronization\ntherapy (CRT).\n\n\"Our revised commercial outlook and need to improve commercial execution have\nled us to make a change in sales leadership,\" said Kevin Hykes, President and\nChief Executive Officer of CVRx. \"I have full confidence in Paul’s ability\nto lead our sales team while we search for a new leader. He knows our\nbusiness, our customers and our commercial strategy, and is well respected by\nthe sales force.  This continuity will serve us well as we work through this\ntransition.\"\n\nAbout CVRx, Inc.\n\nCVRx is a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases. Barostim™ is the first medical\ntechnology approved by FDA that uses neuromodulation to improve the symptoms\nof patients with heart failure. Barostim is an implantable device that\ndelivers electrical pulses to baroreceptors located in the wall of the carotid\nartery. The therapy is designed to restore balance to the autonomic nervous\nsystem and thereby reduce the symptoms of heart failure.\n\nBarostim received the FDA Breakthrough Device designation and is FDA-approved\nfor use in heart failure patients in the U.S. It has been certified as\ncompliant with the EU Medical Device Regulation (MDR) and holds CE Mark\napproval for heart failure and resistant hypertension in the European Economic\nArea. To learn more about Barostim, visit www.cvrx.com.\n\nInvestor Contact:\nMark Klausner or Mike Vallie\nICR Healthcare\n443-213-0501\nir@cvrx.com \n\nMedia Contact:\nEmily Meyers\nCVRx, Inc.\n763-416-2853\nemeyers@cvrx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/04c4feba-7841-4ac8-8ca5-6c03be383a0e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7pPZxD","title":"CVRx Announces Sales Leadership Transition","author":"Globe Newswire","ticker":"CVRX","created":"2026-08-11T11:00:00.458Z","tickers":["CVRX"],"exchange":"NASDAQ","article_body":"MINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)\n(\"CVRx\"), a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases, today announced that Robert John, Chief\nRevenue Officer, will depart the company, and that Paul Verrastro will assume\nthe role of Interim Head of Sales, effective immediately.  In his new role,\nMr. Verrastro will lead CVRx's sales organization while the company conducts a\nsearch for a permanent successor.\n\nMr. Verrastro brings more than 30 years of medical device sales and marketing\nexperience to the role. He has been with CVRx for over five years and recently\nmoved into a new senior advisor role focused on commercial execution\nsupport.  Prior to assuming this role, he was most recently Chief Marketing\nand Strategy Officer. Prior to joining CVRx, he held sales and marketing\nleadership positions at Guidant, Boston Scientific and Medtronic, much of that\nwork focused on bringing novel therapies and technologies to market, including\nimplantable cardioverter defibrillators (ICDs) and cardiac resynchronization\ntherapy (CRT).\n\n\"Our revised commercial outlook and need to improve commercial execution have\nled us to make a change in sales leadership,\" said Kevin Hykes, President and\nChief Executive Officer of CVRx. \"I have full confidence in Paul’s ability\nto lead our sales team while we search for a new leader. He knows our\nbusiness, our customers and our commercial strategy, and is well respected by\nthe sales force.  This continuity will serve us well as we work through this\ntransition.\"\n\nAbout CVRx, Inc.\n\nCVRx is a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases. Barostim™ is the first medical\ntechnology approved by FDA that uses neuromodulation to improve the symptoms\nof patients with heart failure. Barostim is an implantable device that\ndelivers electrical pulses to baroreceptors located in the wall of the carotid\nartery. The therapy is designed to restore balance to the autonomic nervous\nsystem and thereby reduce the symptoms of heart failure.\n\nBarostim received the FDA Breakthrough Device designation and is FDA-approved\nfor use in heart failure patients in the U.S. It has been certified as\ncompliant with the EU Medical Device Regulation (MDR) and holds CE Mark\napproval for heart failure and resistant hypertension in the European Economic\nArea. To learn more about Barostim, visit www.cvrx.com.\n\nInvestor Contact:\nMark Klausner or Mike Vallie\nICR Healthcare\n443-213-0501\nir@cvrx.com \n\nMedia Contact:\nEmily Meyers\nCVRx, Inc.\n763-416-2853\nemeyers@cvrx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/04c4feba-7841-4ac8-8ca5-6c03be383a0e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-11T11:00:00.49695013Z","server_sent_at_ms":1786446000496},"received_at":"2026-08-11T11:00:00.666Z","source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342557/0/en/cvrx-announces-sales-leadership-transition.html"},"analysis":{"id":"104104","press_release_id":"115107","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["CRO departure attributed specifically to need to improve commercial execution","Interim appointment creates leadership uncertainty during search for permanent successor"],"eventType":"executive_change","narrative":"CVRx announced that Chief Revenue Officer Robert John is departing the company, effective immediately, with Paul Verrastro stepping in as Interim Head of Sales.\n\nCEO Kevin Hykes stated that the leadership change was driven by a revised commercial outlook and a specific need to improve execution within the sales organization.\n\nVerrastro, a 30-year industry veteran and current senior advisor, will lead the team while the company searches for a permanent successor.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"CRO departure signals execution issues; internal interim appointed to stabilize."},"keyFigures":null,"quotedText":"Our revised commercial outlook and need to improve commercial execution have led us to make a change in sales leadership","namedEntities":{"people":[{"name":"Robert John","role":"Chief Revenue Officer"},{"name":"Paul Verrastro","role":"Interim Head of Sales"},{"name":"Kevin Hykes","role":"President and CEO"},{"name":"Mark Klausner","role":"Investor Contact"},{"name":"Mike Vallie","role":"Investor Contact"},{"name":"Emily Meyers","role":"Media Contact"}],"products":["Barostim"],"companies":[{"name":"CVRx, Inc.","ticker":"CVRX"},{"name":"Guidant","relationship":"previous employer"},{"name":"Boston Scientific","relationship":"previous employer"},{"name":"Medtronic","relationship":"previous employer"},{"name":"ICR Healthcare","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The departure of the Chief Revenue Officer is significant for a commercial-stage medical device company. The CEO explicitly cited a 'need to improve commercial execution,' signaling potential underperformance in sales, though the appointment of an experienced internal interim mitigates immediate disruption risk."},"tickerRelevance":{"others":[],"primary":"CVRX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"C-level departure with performance concerns"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"CVRx announced that Chief Revenue Officer Robert John is departing the company, effective immediately, with Paul Verrastro stepping in as Interim Head of Sales.\n\nCEO Kevin Hykes stated that the leadership change was driven by a revised commercial outlook and a specific need to improve execution within the sales organization.\n\nVerrastro, a 30-year industry veteran and current senior advisor, will lead the team while the company searches for a permanent successor.","key_figures":null,"named_entities":{"people":[{"name":"Robert John","role":"Chief Revenue Officer"},{"name":"Paul Verrastro","role":"Interim Head of Sales"},{"name":"Kevin Hykes","role":"President and CEO"},{"name":"Mark Klausner","role":"Investor Contact"},{"name":"Mike Vallie","role":"Investor Contact"},{"name":"Emily Meyers","role":"Media Contact"}],"products":["Barostim"],"companies":[{"name":"CVRx, Inc.","ticker":"CVRX"},{"name":"Guidant","relationship":"previous employer"},{"name":"Boston Scientific","relationship":"previous employer"},{"name":"Medtronic","relationship":"previous employer"},{"name":"ICR Healthcare","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-11T11:34:05.751Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"C-level departure with performance concerns"}},"durationMs":247885,"modelName":"glm-4.7"}}